News Headlines

Display #
Title
Pharma Scores Big Win: Trump to Ink FDA User Fee Bill, Saving 5,000 Jobs
Dynavax Shares Plunge on Delayed FDA Decision for Hep B Vaccine Heplisav
Lilly’s acute migraine drug succeeds in late-stage study
AbbVie Wins FDA Approval for the First-Ever Drug to Treat All Forms of Hep C
Mallinckrodt To Snap Up Pennsylvania Drugmaker For Up to $425M
UK finds Roche bladder cancer drug too costly for routine use
U.S. governors urge Trump to make insurance payments
U.S. scientists able to alter genes of human embryos
FDA panel votes against J&J arthritis drug
Regeneron Q2 2017 beats profit estimates
Allergan Reports Continued Strong Execution in Second Quarter 2017 with 9% Increase in GAAP Net Revenues to $4.0 Billion
Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
W2O Group Appoints Mary Corcoran President of Twist
New drug may treat and limit progression of Parkinson's disease
Roche reports strong performance in the first half of 2017
Eight PDUFA Dates to Watch in August 2017
Athenahealth to conduct strategic review amid investor pressure
FDA approves leukemia treatment
Daiichi Sankyo settles U.S. lawsuits over Benicar
Senate plans September hearings on health insurance market
Seattle Genetics Announces Purchase of Bothell Manufacturing Facility from Bristol-Myers Squibb
U.S. FDA Approves Expanded Labeling for Epclusa
Ocular Therapeutix Announces Antony Mattessich Assumes Role as Chief Executive Officer
Anthem to cut back Obamacare plan offerings in California
23andMe Begins Enrollment for First-of-its-Kind Study on Major Depressive and Bipolar Disorders
Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension Approved by U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder
Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration
FDA Panel Votes to Recommend Dynavax’s Hepatitis B Vaccine; Hepsilav Can Compete With GlaxoSmithKline’s Engerix-B
LabCorp Scoops Up Giant CRO for Approximately $1.2 Billion Cash
J&J arthritis drug sirukumab raises safety concerns: FDA staff